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Is it necessary to reduce the 
radioiodine dose in patients with 
thyroid cancer and renal failure?
É necessário reduzir as atividades de radioiodo nas terapias 
de pacientes com câncer de tireoide e disfunção renal?
José Willegaignon1,2, Verena Pinto Brito Ribeiro1, Marcelo Sapienza1,2, 
Carla Ono1,2, Tomoco Watanabe1,2, Carlos Buchpiguel1,2 
summaRy
The	objective	of	 this	 study	were	 to	obtain	dosimetric	 data	 from	a	patient	with	 thyroid	 can-
cer	simultaneously	undergoing	peritoneal	dialysis	therapy,	so	as	to	determine	the	appropriate	
amount	of	 131I	 activity	 to	be	applied	 therapeutically.	Percentages	of	 radioiodine	 in	 the	blood	
and	the	whole-body	were	evaluated,	and	radiation	absorbed	doses	were	calculated	according	
to	OLINDA/EXM	software.	Whole-body	131I	effective	half-time	was	45.5	hours,	being	four	times	
longer	than	for	patients	without	any	renal	dysfunction.	Bone-marrow	absorbed	dose	was	0.074	
mGy/MBq,	with	ablative	procedure	maintenance	at	3.7	GBq,	as	the	reported	absorbed	dose	was	
insufficiently	 restrictive	 to	 change	 the	usual	amount	of	 radioiodine	activity	administered	 for	
ablation.	It	was	concluded	that	radioiodine	therapeutic-dose	adjustment,	based	on	individual	
patient	dosimetry,	is	an	important	way	of	controlling	therapy.	It	also	permits	the	safe	and	po-
tential	delivery	of	higher	doses	of	radiation	to	tumors	and	undesirable	tissues,	with	a	minimum	
of	malignant	effects	on	healthy	tissues.	Arq Bras Endocrinol Metab. 2010;54(4):413-8  
sumáRio
O	objetivo	do	presente	estudo	foi	determinar	a	atividade	de	radioiodo	a	ser	administrada	na	
terapia	de	um	paciente	portador	de	câncer	de	tireoide	e	simultaneamente	tratado	com	diálise	
peritoneal. Percentuais	de	radioiodo	em	sangue	e	corpo-total	foram	avaliados	após	a	adminis-
tração	de	uma	atividade	traçadora	e	a	dosimetria	foi	calculada	utilizando	o	software	OLINDA/
EXM.	A	meia-vida	efetiva	do	radioiodo	em	corpo-total	foi	de	45,5	horas,	sendo	quatro	vezes	
maior	que	aquela	observada	em	pacientes	sem	disfunção	renal.	A	dose	em	medula	óssea	foi	
de	0,074	mGy/MBq,	administrando-se	uma	atividade	terapêutica	de	3,7	GBq,	uma	vez	que	a	
estimativa	de	dose	não	foi	suficientemente	restritiva	para	mudar	a	atividade	usual	de	radioiodo	
com	função	ablativa.	Concluiu-se	que	a	terapia	individualizada	de	pacientes	permite	manter	o	
equilíbrio	entre	o	máximo	de	dose	de	radiação	liberada	em	tumores	ou	tecidos	indesejados	
com	o	mínimo	de	efeitos	maléficos	sobre	tecidos	sadios.	Arq Bras Endocrinol Metab. 2010;54(4):413-8
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Thyroid cancer is the most frequently occurring en-docrinal tumor, although it represents less than 
1% of all malignant tumors diagnosed worldwide (1). 
Patient management usually consists of thyroidectomy, 
either entire or nearly so, followed by radioiodine thera-
py in the case of differentiated thyroid cancer (papillary 
and follicular tumors).
Radioiodine therapy is applied in the removal of re-
manent thyroid tissue after gland surgery, and in the tre-
atment of metastases, eventually suspected or detected 
by clinical diagnosis, accordingly clinically important, 
especially in reducing recurrence (2).
Around ninety percent of administered radioiodine 
activity is excreted mainly through the kidneys. Thus, 
patients with renal insufficiency may retain radioiodi-
ne activity over a long period, thereby leading to more 
intense internal exposure to radiation than that obser-
ved in normal ones (3). Reports on patients with re-
nal dysfunction simultaneously undergoing radioiodine 
treatment are rare in literature (4), although less so as 
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131I therapy and renal failure
regards concurring hemodialysis. Consequently, there 
is little information available on radioiodine biokinetics 
as well as radiation dosimetry in patients with differen-
tiated thyroid cancer (DTC) which are simultaneously 
undergoing continuous peritoneal dialysis (5-7). This 
lack of information gives rise to difficulties in determi-
ning the appropriate 131I activities to be administered 
in this specific case. With this in mind, the expressed 
aim was to provide an alternative for defining the ideal 
dose in patient therapy, based on individually acquired 
radiometric data as well as to discuss the importance of 
this individualized approach in patients with renal insu-
fficiency and in need of radioiodine therapy. 
case RePoRT
A 49-year-old female patient was diagnosed with DTC, 
a multicentric papillary microcarcinoma, with a follicu-
lar variant in both lobes. The largest tumor measuring 
0.6 cm at the widest point and without cervical lymph 
node involvement (T1aNoMo). The patient was admit-
ted for additional treatment with radioiodine therapy, 
in order to remove remanent thyroid tissue. Further-
more, and due to renal insufficiency, she was also sub-
mitted to once-daily and continuous peritoneal dialysis 
therapy while awaiting renal transplant. Identified as a 
rare case, and with the lack of information on radioio-
dine therapy under similar circumstances, she was sub-
mitted to a maximum-safe-dose procedure. The inten-
tion was to estimate the absolutely safest administrable 
activity, without the risk of severe medullar depression. 
This was based on the biokinetics of radioiodine excre-
tion and retention, and on dose estimates for internal 
organs, especially the bone-marrow, by unit of adminis-
tered activity. In order to thus proceed and write this 
report a signed informed consent was obtained from 
the patient.
Although it is questionable whether radioiodine 
therapy should be resorted to in low-risk or very low-
risk thyroid cancer patients, this particular one was trea-
ted on physician’s recommendation. Furthermore, our 
lack of experience with this kind of subject led us to 
carry out conservative and well-established procedures 
without the use of rhTSH in this particular case. 
After prior preparation for a logistic period of 35 
days, by means of an iodine-poor diet and the suppres-
sion of hormonal reposition (thyroxine), TSH level 
reached 455 mU/mL, thyroglobulin 6.0 ng/mL and 
anti-thyroglobulin negative. At this point, 74 MBq (2 
mCi) of 131I activity was administered orally in order to 
study internal radiotracer biokinetics. Absorbable doses 
of radiation by internal organs (Table 1) were furnished 
by OLINDA/EXM (8) software using a specific resi-
dence time of radioiodine in the patient’s whole-body, 
corrected according to the patient’s weight (113 kg) 
and estimated bone-marrow mass (2.4 kg), and calcu-
lated by assuming its variation against patient weight, as 
indicated by other authors (9).
Table 1.  Estimated radiation absorbed dose to certain internal organs per 
unit of administered radioiodine activity
internal organ
absorbed 
radiation
dose  
(mGy/mbq)b
internal organ
absorbed 
radiation 
dose  
(mGy/mbq)
Brain 0.113 Ovaries 0.148
Heart wall 0.141 Uterus 0.147
Liver 0.137 Stomach wall 0.140
Lungs 0.128 Pancreas 0.150
Red marrow 0.074 Spleen 0.137
Thyroid remaindea 78.700 Small intestine 0.137
Whole-body 0.096 Breasts 0.105
a Assuming 0.3 g of weight, and considering a radioiodine uptake of 1% of administered activity 
per gram of thyroid tissue; b 1 mGy/MBq = 37 mGy/mCi.
The percentage of radioiodine in the blood and 
entire-body were calculated at 2, 4, 24, 48, 72 and 96 
hours post-activity administration. Samples of dialyzed 
liquid were also analyzed so as to obtain the percentage 
of radioiodine activity excreted thereby. Activities in the 
blood and dialyzed liquid samples (2 mL) were estima-
ted by using a 131I standard source of like volume, and 
a radiation detector signal (CPM, Counts Per Minute) 
provided by a well-counter (Captus 600 Well Counter 
System, Capintec Inc.). Before using the well-counter, 
the radiation detector was performance-tested by using 
a 137Cs standard source of 500 nCi (Lot # 693-56-
3/01-Jun-00). The maximum deviation between acti-
vities, as estimated by the detector, and the theoretical 
activity of the source, was 7.0%. Each organic sample 
from the patient was measured five times, the time of 
measurement lasting two minutes. Standard deviation 
in all measurements was about 1.5%. 
Radioiodine uptake in the thyroid bed was asses-
sed using a Captus 600 (Thyroid Uptake System, SN: 
600269, Capintec Inc.). The patient herself was used 
as standard source for evaluating the remaining activity 
in her body, as a function of time versus post-activity 
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administration. Slight renal activity with residual urine 
was observed in the patient. The activity level excreted 
thereby was not measured.
Whole-body scans were carried out at 4, 24, 48, 72 
and 96 hours post-activity administration by using a 
gamma-camera (Model ECAM Gantry Dual Head Ex-
tended, SN: 7086, SIEMENS Medical System – USA). 
The pattern of radioiodine reduction throughout the 
whole-body and in the blood as a function of time and 
given the radioiodine effective half-time in both com-
partments can be seen in figure 1. Figure 2, shows the 
percentages of accumulated activity extracted from the 
patient’s body as a function of elapsed time versus post-
activity administration. Certain characteristics of each 
dialysis procedure undertaken until the fourth day post-
activity administration are presented in table 2. Anterior 
and posterior images of the whole-body are shown in 
figure 3, together with some of the drawn ROIs used 
for complementary dosimetric studies.  
On considering the radiation dose delivered to bo-
ne-marrow per unit of administered activity as 0.074 
mGy/MBq (2.738 mGy/mCi), as indicated by OLIN-
DA/EXM computational software, and based on in-
formation from Benua (10) to the effect that 2 Gy in 
bone-marrow is a safe dose, the absolutely safest ac-
tivity to be applied in patient therapy would be 26.8 
GBq (730 mCi). This was reduced to 3.7 GBq (100 
mCi) for ablation, since the estimated absorbed dose of 
radiation to bone marrow was insufficiently restrictive 
to change the usual amount of radioiodine activity spe-
cifically administered. 
figure 1. Percentage of administered activity in whole-body and blood as 
a function of elapsed time post-activity administration.
figure 2. Percentage of accumulated activity extracted from the patient’s 
body as a function of elapsed time post-activity administration.
figure 3. Whole-body scan with respective ROIs drawn for complementary 
dosimetric studies.
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results being strongly dependant on the dialytic me-
thodology resorted to. In a case of 6 hourly-successive 
dialysis, Wang and cols. (4) reported the total excretion 
of 60% of administered activity at each dialytic session, 
and a retention index of 6.4% and 2.6% of total admi-
nistered activity at 18 hours and 24 hours post-activity 
administration, respectively. For Toubert and cols. (7), 
daily clearance was 5.3% to 8.6% of the total adminis-
tered activity over the first three days post-activity ad-
ministration. Kaptein and cols. (6) presented similar 
results, with 26.9% mean elimination at each session 
of dialysis, 24 hours after activity administration. Holst 
and cols. (3) showed that the percentage of 131I in a 
session of hemodialysis ranged from a minimum of 38% 
up to a maximum of 80% of all activity existing inside 
the patient’s body before initiating the procedure. 
Moreover, Holst and cols. (3) confirmed the variabi-
lity of radioiodine clearance at each session. This varied 
according to the type of dialysis employed (hemodialy-
sis or peritoneal dialysis), and depended on the internal 
characteristics of each patient, the peritoneal membrane 
of each, the duration of each dialysis, the elapsed time 
between activity administration and the first dialysis, the 
elapsed time between two successive dialyses, and glu-
cose concentration, besides other factors.
Use has been made of several different methodolo-
gies in order to determine the optimal amount of ra-
dioiodine activity to be administered to patients with 
impaired renal function, with a view to eradicating re-
manent thyroid tissue after clinical surgery. Some au-
thors have given activities based on delivering 300 Gy 
to this tissue (7), whereas others have chosen to reduce 
these to about 25% in the case of administration to pa-
tients without renal dysfunction (6,7). In a comparative 
study by Holst and cols. (3), it was shown that certain 
authors applied activities as low as 0.92 GBq (25 mCi) 
and as high as 9.2 GBq (250 mCi) in the treatment of 
patients with impaired renal function. They placed in 
evidence the lack of consensus on the level of radioiodi-
ne activity necessary for therapy, and at the same time, 
safe for patients with thyroid cancer and simultaneously 
undergoing hemodialysis or peritoneal dialysis. Yet, it is 
noteworthy that whether applying low or high activity, 
many patients required further treatment with radio-
iodine for a persistent disease. This was probably due 
to the dose of absorbed radiation achieved being insu-
fficient to meet the patient’s needs, either for ablative 
or therapeutic purposes. One example of this can be 
extracted from the work of Wang and cols. (4), where 
Table 2. Some characteristics of each dialytic procedure performed until 
the fourth day post-tracer-activity administration
Day
Dialysis 
volume
(ml)
activity 
concentration
(kbq/ml)
overall 
activity 
(mbq)a
Percentage of 
administered 
activity
First 13,492 0.720 ± 0.011 9.77 ± 0.15 13.20 ± 0.20
Second 13,510 1.07 ± 0.016  14.43 ± 0.22 19.50 ± 0.29
Thirth 13,452 0.420 ± 0.006 5.70 ± 0.09 7.70 ± 0.12
Fourth 13,389 0.270 ± 0.004 3.66 ± 0.05 4.90 ± 0.07
a 1 MBq = 0.027 mCi.
Discussion
Prolonged 131I retention inside a patient’s body is di-
rectly associated to the more probable appearance and 
severity of side-effects, as, for instance, sialoadenitis, 
xerostomia and gastritis, besides bone-marrow depres-
sion. This is due to the absorbed doses of radiation re-
ceived by exposed internal organs during radioiodine 
therapy. Additional exposure is even liable to increase 
citogenetic alterations in blood constituents. 
Apart from the excessive exposure to radiation un-
dergone by the patients themselves, the delay in elimi-
nating radioiodine may expose relatives, medical staff 
and others with added intensity. So unquestionably, 
there is still the need for further attention whenever 
radiopharmaceutical activities are being administered 
to patients with renal dysfunction.
The study of radioiodine biokinetics in the present 
case, led the way to defining a radioiodine-effective 
half-time of 45.5 hours (Figure 1) for the patient’s 
whole-body, with residence time being estimated at 
53.52 hours. These values are approximately 4 times 
greater than those estimated for patients with normal 
renal functions, where the values are 11.4 hours and 
16.4 hours (11), respectively. 
The dialysis process employed over the first four 
days post-tracer-activity administration led to the re-
moval of 45% of all administered activity, a clearance 
rate of 0.5% per hour, with a mean concentration of 
0.62 kBq (0.02 mCi) per mL dialyzed (Table 2 and Fi-
gure 2). Radioiodine uptake by the thyroid bed was 
0.3% of total administered activity, as indicated through 
ROI methodology and direct measurement by using a 
specific thyroid uptake detector (Figure 3).
Apart from the specific removal rate observed in 
this particular patient, several studies have indicated 
that the percentage of radioiodine removed in one sin-
gle session of dialysis varies from patient to patient, the 
131I therapy and renal failure
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they administered an activity of 5.5 GBq (150 mCi) 
to a patient after observing that an activity of 1.1 GBq 
(30 mCi) produced an insufficiently absorbed dose for 
treatment.
With the aim of maintaining the absorbed dose in 
the bone-marrow of patients with renal dysfunction 
and simultaneously undergoing peritoneal dialysis, 
equal to that received by patients with preserved renal 
functions, Kaptein and cols. (6) reduced the usual acti-
vity from 5.5 GBq (150 mCi) to 0.98 GBq (26.6 mCi) 
and 1.1 GBq (29.9 mCi) in the therapy of two patients 
thus being treated. Moreover, on considering an esti-
mation of 300 Gy in remanent thyroid tissue which was 
ultrasonographically evaluated at 0.6 g, Toubert and 
cols. (7) indicated an activity of 0.81 GBq (22 mCi) for 
a patient undergoing peritoneal dialysis, instead of the 
usual activity of 3.7 GBq (100 mCi) for ablation.
The definition of radioiodine activities based on an 
estimation of 300 Gy in remanent thyroid tissue is still 
quite questionable. This is mainly due to the uncertain-
ties and limitations of each method when estimating 
the amount of tissue involved. Tissue mass estimated by 
ultrasonography, scintigraphy or radioiodine uptake in 
the cervical area may incur inaccuracy and innate diffi-
culties in determining volumetric and mass dimensions 
in structures with a highly variable morphology. This 
occurs through using imprecise measurement metho-
dologies as well as the extreme variability in radioiodine 
uptake brought about by the functional behavior of the 
remaining cells in the thyroid bed after surgery (12-15).
The above-mentioned points exemplify the diffe-
rent ways by which specialists adapt the administration 
of radioiodine activity to patients with various forms of 
thyroid cancer and impaired renal functions. However, 
and apart from this, the main point under considera-
tion is to identify the plausible amount of radioiodine 
activity to be administered, so as to reach the maxi-
mum probability of eradicating remanent thyroid tis-
sue or metastases, with a minimum of side effects from 
radioiodine therapy itself. It seems that the answer to 
this question doubtlessly points to determining acti-
vities based on biokinetics and individual dosimetry. 
A further consideration is that side effects are produced 
by the absorbed radiation dose, which is, in turn, direc-
tly proportional to radioiodine uptake and its time of 
retention inside the patient’s body.
When considering that patients with thyroid cancer 
who are at the same time undergoing peritoneal dialy-
sis, are rare cases, it is statistically difficult to analyze the 
efficiency of radioiodine therapy therein. Nevertheless, 
it is possible to have some idea when observing thera-
peutic efficiency in patients without renal dysfunction. 
In literature, activities as low as 1.8 GBq (50 mCi) or 
1.1 GBq (30 mCi) have failed in therapy in about 40% 
to 50% of the cases (16-18), when prior dosimetric 
studies were unavailable. Thus, the administration of 
similar activities to patients should be avoided, except 
in specific and documented cases, or when dosimetric 
studies have preceded therapy. 
In the present specific case, the absorbed dose recei-
ved by the whole-body was estimated at 0.096 mGy/
MBq (3.55 mGy/mCi), and by the bone-marrow 
0.074 mGy/MBq (2.738 mGy/mCi). These values 
were 2.2 and 1.9 times higher than those estimated for 
patients without renal dysfunction, estimated at 0.044 
mGy/MBq (1.628 mGy/mCi) for the whole-body 
and 0.038 mGy/MBq (1.406 mGy/mCi) for bone-
marrow, respectively. Based on the dose of absorbed ra-
diation delivered to the bone-marrow per administered 
activity, and 2 Gy (10) as being a safe limit for avoiding 
significant medullary depression, the absolutely safest 
activity to be applied in the therapy under considera-
tion would be 26.8 GBq (730 mCi). 
Furthermore, an ablative procedure with 3.7 GBq 
(100 mCi) was indicated, on considering the clinical 
stage of the disease, the safest applicable activity and the 
possibility of obtaining low efficacy when applying small 
doses. In addition, the reported absorbed doses were 
not restrictive enough to reduce the usual amount of ra-
dioiodine activity administered to patients for ablation.
A limitating factor in the present work was not ha-
ving previously compared biokinetic and dosimetric 
data obtained from tracer-activity administration with 
those from therapeutic procedures. In the latter, only ra-
dioiodine effective half-time in the patient’s whole-body 
was estimated. Even so, this was done by using a diffe-
rent way of measuring (exposure rates at 1.0 m from the 
patient’s body using a Geiger-Müller detector). Thus, 
all absorbed radiation doses were assessed only on con-
sidering radiometric data from tracer studies. 
On considering the rare occurrence of thyroid can-
cer in patients with renal dysfunction and undergoing 
peritoneal dialysis, with scarce mention in current lite-
rature, it is our belief that there will be some delay in 
arriving at a consensus on the ideal management of this 
type of patient. This situation will persist, at least un-
til an appreciable amount of radiometric data has been 
accumulated and fresh studies undertaken, thereby gi-
131I therapy and renal failure
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
418 Arq Bras Endocrinol Metab. 2010;54/4
ving rise to novel considerations, and the availability 
of improved alternatives for treatment. Thus, the fun-
damental intention hereby is not to add a novel thera-
peutic model for application in like situations, but to 
aggregate radiometric data from a real-life case. This 
would validate the use of individual dosimetry, thereby 
leading to a more individualized therapy. This, in our 
opinion, is the future path for any type of treatment 
based on radiopharmaceutical therapy.
In conclusion, the adjustment of radioiodine thera-
peutic doses based on individual patient dosimetry is an 
important way of keeping therapy under control. This 
would permit the safe and potential delivery of higher 
doses of radiation to tumors and undesirable tissues, 
with minimal malignant side-effects. This is the reason 
for concentrated attention in the treatment of patients 
suffering from renal failure. 
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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